Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group

BACKGROUND: Sunitinib malate, a targeted tyrosine kinase inhibitor, is standard of care for metastatic renal cell carcinoma (mRCC) and serves as the active comparator in several ongoing mRCC clinical trials. This analysis reports benchmarks for clinical outcomes based on International Metastatic Ren...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Genitourin Cancer
Main Authors: Rini, Brian I, Hutson, Thomas E., Figlin, Robert A., Lechuga, Maria Josè, Valota, Olga, Serfass, Lucile, Rosbrook, Brad, Motzer, Robert J.
Format: Artigo
Sprog:Inglês
Udgivet: 2018
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6690431/
https://ncbi.nlm.nih.gov/pubmed/29853320
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2018.04.005
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker